Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause

• Status: Completed
• Trial end date: 2007-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective in the treatment of moderate to severe vasomotor symptoms associated with menopause.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Bazedoxifene; Estrogens; Estrogens, Conjugated (USP)

Criteria

Inclusion Criteria:

• Generally healthy, postmenopausal women, aged 40 to 64, with last natural menstrual period completed at lease 6 months ago

• Intact uterus

• Seeking treatment for hot flushes and experiencing 7 moderate to severe hot flushes per day or 50 per week

Exclusion Criteria:

• History of active presence of thrombophlebitis, thrombosis, thromboembolic disorders

• History of active presence of stroke, TIA, heart attack or ischemic heart disease

• History of melanoma, breast or any gynecologic cancer at any time; history of any other cancer within the past 5 years